<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00528567</url>
  </required_header>
  <id_info>
    <org_study_id>BO20289</org_study_id>
    <secondary_id>2007-001128-11</secondary_id>
    <nct_id>NCT00528567</nct_id>
  </id_info>
  <brief_title>BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer</brief_title>
  <official_title>An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in &quot;Triple Negative&quot; Breast Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      The main objective of the trial is to compare Invasive Disease-Free Survival (IDFS) of
      patients randomised to treatment with adjuvant chemotherapy alone or to adjuvant chemotherapy
      with 1 year of bevacizumab.

      The secondary objectives of this trial are to:

        -  compare Overall Survival (OS), Breast Cancer-Free Interval (BCFI), Disease- Free
           Survival (DFS) and Distant Disease-Free Survival (DDFS) of patients randomised to
           treatment with adjuvant chemotherapy alone or to adjuvant chemotherapy in combination
           with 1 year of bevacizumab

        -  evaluate the safety and tolerability of bevacizumab

      An exploratory sub-study (not reported here) was to identify biomarkers (from tumour or
      serum) predictive of toxicity and for the level of benefit from the addition of bevacizumab
      to standard adjuvant systemic treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Invasive Disease-free Survival (IDFS) Event</measure>
    <time_frame>Event driven (until data cutoff: 29 February 2012: up to 49 months)</time_frame>
    <description>IDFS, was a composite endpoint defined as the time from randomization until the date of the first occurrence of one of the following events: Ipsilateral invasive breast cancer recurrence (same breast); Ipsilateral (same side of body) local regional invasive breast cancer recurrence (axilla, regional lymph nodes, chest wall, and/or skin); Distant recurrence (evidence of breast cancer in any anatomic site);Death attributable to any cause; Contralateral (opposite side of the body) invasive breast cancer or Second primary non-breast invasive cancer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Invasive Disease-free Survival (IDFS) Events</measure>
    <time_frame>Event driven (until data cutoff: 29 February 2012 up to 49 months)</time_frame>
    <description>IDFS, was a composite endpoint defined as the time from randomization until the date of the first occurrence of one of the following events: Ipsilateral invasive breast cancer recurrence (same breast); Ipsilateral (same side of body) local regional invasive breast cancer recurrence (axilla, regional lymph nodes, chest wall, and/or skin); Distant recurrence (evidence of breast cancer in any anatomic site);Death attributable to any cause; Contralateral (opposite side of the body) invasive breast cancer or Second primary non-breast invasive cancer. The percentage of participants with and without IDFS Events by the time of the data cutoff is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Invasive Disease-free Survival (IDFS) Event Excluding Second Primary Non-Breast Invasive Cancer</measure>
    <time_frame>Event driven (until data cutoff: 29 February 2012: up to 49 months)</time_frame>
    <description>IDFS, was a composite endpoint defined as the time from randomization until the date of the first occurrence of one of the following events: Ipsilateral invasive breast cancer recurrence (same breast); Ipsilateral (same side of body) local regional invasive breast cancer recurrence (axilla, regional lymph nodes, chest wall, and/or skin); Distant recurrence (evidence of breast cancer in any anatomic site); Death attributable to any cause; Contralateral (opposite side of the body) invasive breast cancer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Invasive Disease-free Survival (IDFS) Events Excluding Second Primary Non-Breast Invasive Cancer</measure>
    <time_frame>Event driven (until data cutoff: 29 February 2012: up to 49 months)</time_frame>
    <description>IDFS, was a composite endpoint defined as the time from randomization until the date of the first occurrence of one of the following events: Ipsilateral invasive breast cancer recurrence (same breast); Ipsilateral (same side of body) local regional invasive breast cancer recurrence (axilla, regional lymph nodes, chest wall, and/or skin); Distant recurrence (evidence of breast cancer in any anatomic site); Death attributable to any cause; Contralateral (opposite side of the body) invasive breast cancer. Percentage of participants with and without IDFS Events by the time of data cutoff is presented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Overall Survival (OS) Event</measure>
    <time_frame>Event driven (until data cutoff: 29 February 2012: up to 49 months)</time_frame>
    <description>OS was defined as the time from randomization to death attributable to any cause. Patients for whom no death is captured in the clinical database up to the clinical cut-off date are censored at the last time they were known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Overall Survival (OS) Event</measure>
    <time_frame>Event driven (until data cutoff: 30 June 2014: up to 77 months)</time_frame>
    <description>OS was defined as the time from randomization to death attributable to any cause. Patients for whom no death is captured in the clinical database up to the clinical cut-off date are censored at the last time they were known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Overall Survival (OS) Event</measure>
    <time_frame>Event driven (until data cut off: 29 February 2012: up to 49 months)</time_frame>
    <description>OS was defined as the time from randomization to death attributable to any cause. Patients for whom no death is captured in the clinical database up to the clinical cut-off date are censored at the last time they were known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Overall Survival (OS) Event</measure>
    <time_frame>Event driven (until data cut off: 30 June 2014: up to 77 months)</time_frame>
    <description>OS was defined as the time from randomization to death attributable to any cause. Patients for whom no death is captured in the clinical database up to the clinical cut-off date are censored at the last time they were known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Breast Cancer-Free Interval (BCFI) Event</measure>
    <time_frame>Event driven (until data cutoff: 29 February 2012: up to 49 months)</time_frame>
    <description>BCFI is defined as the time from randomization until the date of the first occurrence of one of the following events: Ipsilateral local/regional invasive breast cancer recurrence or distant breast cancer recurrence; Contralateral invasive breast cancer; Ipsilateral or contralateral Ductal carcinoma in situ or Death only from breast cancer cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Breast Cancer-Free Interval (BCFI) Events</measure>
    <time_frame>Event driven (until data cutoff: 29 February 2012: up to 49 months)</time_frame>
    <description>BCFI is defined as the time from randomization until the date of the first occurrence of one of the following events: Ipsilateral local/regional invasive breast cancer recurrence or distant breast cancer recurrence; Contralateral invasive breast cancer; Ipsilateral or contralateral DCIS or Death only from breast cancer cause. Percentage of participants with and without BCFI events by the time of the data cutoff is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Disease-Free Survival (DFS) Event</measure>
    <time_frame>Event driven (until data cutoff: 29 February 2012: up to 49 months)</time_frame>
    <description>DFS is defined as the time from randomization until the date of the first occurrence of one of the following events: Ipsilateral invasive breast cancer recurrence (same breast); Ipsilateral (same side of body) local regional invasive breast cancer recurrence (axilla, regional lymph nodes, chest wall, and/or skin); Distant recurrence (evidence of breast cancer in any anatomic site); Death attributable to any cause; Contralateral (opposite side of the body) invasive breast cancer, Second primary non-breast invasive cancer or New diagnosis of an ipsilateral or contralateral Ductal carcinoma in situ (DCIS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Disease-Free Survival (DFS) Events</measure>
    <time_frame>Event driven (until data cutoff: 29 February 2012: up to 49 months)</time_frame>
    <description>DFS is defined as the time from randomization until the date of the first occurrence of one of the following events: Ipsilateral invasive breast cancer recurrence (same breast); Ipsilateral (same side of body) local regional invasive breast cancer recurrence (axilla, regional lymph nodes, chest wall, and/or skin); Distant recurrence (evidence of breast cancer in any anatomic site); Death attributable to any cause; Contralateral (opposite side of the body) invasive breast cancer, Second primary non-breast invasive cancer or New diagnosis of an ipsilateral or contralateral Ductal carcinoma in situ (DCIS). Percentage of Participants with and without DFI Events by the time of the data cut-off is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Distant Disease-Free Survival (DDFS) Event</measure>
    <time_frame>Event driven (until data cutoff: 29 February 2012: up to 49 months)</time_frame>
    <description>DDFS is defined as the time from randomization until the date of the first occurrence of one of the following events: Distant recurrence; Death attributable to any cause; Second primary non-breast invasive cancer (with the exception of non-melanoma Skin cancers).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Distant Disease-Free Survival (DDFS) Events</measure>
    <time_frame>Event driven (until data cutoff: 29 February 2012: up to 49 months)</time_frame>
    <description>DDFS is defined as the time from randomization until the date of the first occurrence of one of the following events: Distant recurrence; Death attributable to any cause; Second primary non-breast invasive cancer (with the exception of non-melanoma Skin cancers). Percentage of participants with and without DDFS Events by the time of the data cutoff is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Adverse Events (SAEs), Adverse Events (AEs) and Deaths</measure>
    <time_frame>Through end of study: 30 June 2014: up to 77 months</time_frame>
    <description>An adverse event was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events.
A serious adverse event is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is Life-Threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2591</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Bevacizumab and Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to receive bevacizumab in combination with chemotherapy as prescribed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants randomized to receive standard adjuvant chemotherapy as prescribed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab was administered at a dose equivalent of 5 mg/kg/week using 1 of 3 different scheduling options depending on the schedule of the adjuvant chemotherapy regimen selected for an individual patient.</description>
    <arm_group_label>Bevacizumab and Chemotherapy</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard adjuvant chemotherapy</intervention_name>
    <description>All chemotherapy schedules and doses for each patient were prescribed according to the labeled indication of the country in which the patient was receiving therapy.</description>
    <arm_group_label>Bevacizumab and Chemotherapy</arm_group_label>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult patients, &gt;=18 years of age;

          -  operable primary invasive breast cancer;

          -  completed definitive loco-regional surgery;

          -  primary tumor centrally confirmed as triple negative.

        Exclusion Criteria:

          -  locally advanced breast cancers;

          -  previous breast cancer history;

          -  clinically significant cardiovascular disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <zip>94904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pleasant Hill</city>
        <state>California</state>
        <zip>94523</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fairfield</city>
        <state>Connecticut</state>
        <zip>06824</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <zip>33321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Niles</city>
        <state>Illinois</state>
        <zip>60714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Waterloo</city>
        <state>Iowa</state>
        <zip>50702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850-3348</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brownstown</city>
        <state>Michigan</state>
        <zip>48183</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <zip>48075-3707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Long Branch</city>
        <state>New Jersey</state>
        <zip>07740</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10469</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Middletown</city>
        <state>Ohio</state>
        <zip>45042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rutland</city>
        <state>Vermont</state>
        <zip>05701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Abingdon</city>
        <state>Virginia</state>
        <zip>24211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <zip>C1405DCS</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rosario</city>
        <zip>S2002KDS</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brisbane</city>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brisbane</city>
        <zip>4104</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Camperdown</city>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>East Bentleigh</city>
        <zip>VIC 3165</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fitzroy</city>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Geelong</city>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kurralta Park</city>
        <zip>5035</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Malvern</city>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nambour</city>
        <zip>4560</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Parkville</city>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perth</city>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perth</city>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Port Macquarie</city>
        <zip>2444</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Leonards</city>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sydney</city>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sydney</city>
        <zip>2060</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sydney</city>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sydney</city>
        <zip>2139</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wahroonga</city>
        <zip>2076</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Waratah</city>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wodonga</city>
        <zip>3690</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wollongong</city>
        <zip>2500</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bludesch</city>
        <zip>6712</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krems</city>
        <zip>4560</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leoben</city>
        <zip>8700</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wels</city>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wiener Neustadt</city>
        <zip>2700</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wolfsberg</city>
        <zip>9400</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baudour</city>
        <zip>7331</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sint-niklaas</city>
        <zip>9100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tournai</city>
        <zip>7500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wilrijk</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sarajevo</city>
        <zip>71000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goiania</city>
        <zip>74075-040</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ijui</city>
        <zip>98700-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>JAU</city>
        <zip>17210-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto Alegre</city>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto Alegre</city>
        <zip>90430-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto Alegre</city>
        <zip>91350-200</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rio de Janeiro</city>
        <zip>22260-020</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santo Andre</city>
        <zip>09060-870</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <zip>01209-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <zip>01317-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <zip>05403</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <zip>1401000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sorocaba</city>
        <zip>18030-245</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2H 2A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 6Z8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 5P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <zip>N2G 1G3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5M 2N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1G 2B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 5J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9N 1N8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 2X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quebec</city>
        <zip>G1S 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100071</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Changchun</city>
        <zip>130012</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chengdu</city>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fuzhou</city>
        <zip>350025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guangzhou</city>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hang Zhou</city>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suzhou</city>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tianjin</city>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wuhan</city>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zhejiang</city>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Jose</city>
        <zip>10103</zip>
        <country>Costa Rica</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brno</city>
        <zip>656 53</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Novy Jicin</city>
        <zip>741 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pardubice</city>
        <zip>532 03</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha</city>
        <zip>150 06</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampere</city>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Turku</city>
        <zip>20521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bayonne</city>
        <zip>64100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bordeaux</city>
        <zip>33077</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63050</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Colmar</city>
        <zip>68024</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grenoble</city>
        <zip>38100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Chaussee St Victor</city>
        <zip>41260</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Limoges</city>
        <zip>87039</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marseille</city>
        <zip>13285</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montbeliard</city>
        <zip>25209</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mougins</city>
        <zip>6250</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nancy</city>
        <zip>54100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Neuilly Sur Seine</city>
        <zip>92200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75231</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint-cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Senlis</city>
        <zip>60309</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Strasbourg</city>
        <zip>67010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulon</city>
        <zip>83056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>10317</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>14195</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bielefeld</city>
        <zip>33604</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bonn</city>
        <zip>53111</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chemnitz</city>
        <zip>09116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coburg</city>
        <zip>96450</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt Am Main</city>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Georgsmarienhtte</city>
        <zip>49124</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greifswald</city>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <zip>20357</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <zip>69115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Herne</city>
        <zip>44625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kassel</city>
        <zip>34117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Koeln</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krefeld</city>
        <zip>47805</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leipzig</city>
        <zip>04129</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lemgo</city>
        <zip>32657</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lneburg</city>
        <zip>21339</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Magdeburg</city>
        <zip>39108</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mnchen</city>
        <zip>81925</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mnster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Offenbach</city>
        <zip>63069</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Offenburg</city>
        <zip>77654</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Recklinghausen</city>
        <zip>45657</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rosenheim</city>
        <zip>83022</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stade</city>
        <zip>21680</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trier</city>
        <zip>54290</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tbingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>ULM</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>WEIENFELS</city>
        <zip>06667</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wiesbaden</city>
        <zip>65199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Witten</city>
        <zip>58452</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heraklion</city>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Patras</city>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Thessaloniki</city>
        <zip>56429</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hong Kong</city>
        <zip>852</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kfar Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ramat-gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aviano</city>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bari</city>
        <zip>70126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bergamo</city>
        <zip>24128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brindisi</city>
        <zip>72100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Candiolo</city>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cattolica</city>
        <zip>47841</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cesena</city>
        <zip>47023</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fano</city>
        <zip>61032</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Genova</city>
        <zip>16142</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lecce</city>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lido Di Camaiore</city>
        <zip>55043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Livorno</city>
        <zip>57100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lugo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mantova</city>
        <zip>46100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Noale</city>
        <zip>30033</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palermo</city>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Parma</city>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Potenza</city>
        <zip>85100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ravenna</city>
        <zip>48100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rimini</city>
        <zip>47037</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <zip>00158</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rozzano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Giovanni Rotondo</city>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sassari</city>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taormina</city>
        <zip>98039</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Treviglio</city>
        <zip>24047</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vecchiazzano</city>
        <zip>47100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aichi</city>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ehime</city>
        <zip>791-0280</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka</city>
        <zip>811-1395</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyoto</city>
        <zip>606-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <zip>540-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saitama</city>
        <zip>350-1298</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <zip>104-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <zip>113-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyunggi-do</city>
        <zip>411-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>135-170</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>137-702</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Skopje</city>
        <zip>1000</zip>
        <country>Macedonia, The Former Yugoslav Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kelantan</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Penang</city>
        <zip>11200</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petaling Jaya, Selangor</city>
        <zip>46050</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Selangor</city>
        <zip>47500</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leon</city>
        <zip>37000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monterrey</city>
        <zip>64020</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Delftzijl</city>
        <zip>9934 JD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Den Helder</city>
        <zip>1782GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tilburg</city>
        <zip>5042 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wellington</city>
        <zip>6002</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lima</city>
        <zip>11</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cebu</city>
        <zip>6000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quezon City</city>
        <zip>1114</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elblag</city>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <zip>93-509</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <zip>20-081</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <zip>20-090</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznan</city>
        <zip>61-878</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warsaw</city>
        <zip>61485</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lisboa</city>
        <zip>1099-023</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucharest</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cluj Napoca</city>
        <zip>400015</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chelyabinsk</city>
        <zip>454 087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ekaterinburg</city>
        <zip>620905</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ivanovo</city>
        <zip>153040</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kazan</city>
        <zip>420029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kazan</city>
        <zip>420111</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>117837</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>121356</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Obninsk</city>
        <zip>249036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Persochnysaint-petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ryazan</city>
        <zip>390011</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Samara</city>
        <zip>443066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>UFA</city>
        <zip>450054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sremska Kamenica</city>
        <zip>21204</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bloemfontein</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durban</city>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johannesburg</city>
        <zip>2196</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pietermaritzburg</city>
        <zip>3201</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pretoria</city>
        <zip>0002</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pretoria</city>
        <zip>0181</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burgos</city>
        <zip>09005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gijon</city>
        <zip>33394</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Laguna</city>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mataro</city>
        <zip>08304</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mlaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Navarra</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pontevedra</city>
        <zip>36002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Terrassa</city>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eskilstuna</city>
        <zip>63188</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gaevle</city>
        <zip>80187</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lund</city>
        <zip>22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Malmoe</city>
        <zip>20502</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Umea</city>
        <zip>90185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aarau</city>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chur</city>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Thun</city>
        <zip>3600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winterthur</city>
        <zip>8401</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zrich</city>
        <zip>8008</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Changhua</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaohsiung</city>
        <zip>813</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Songkhla</city>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belfast</city>
        <zip>BT9 7AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bournemouth</city>
        <zip>BH7 7DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brighton</city>
        <zip>BN2 5BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bristol</city>
        <zip>BS2 8ED</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cambridge</city>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cardiff</city>
        <zip>CF14 2TL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chelsmford</city>
        <zip>CM1 7ET</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Colchester</city>
        <zip>CO3 3NB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dundee</city>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Epping</city>
        <zip>CM16 6TN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Exeter</city>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guildford</city>
        <zip>GU2 5XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huddersfield</city>
        <zip>HD3 3EA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ipswich</city>
        <zip>IP4 5PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>EC1 A7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Merseyside</city>
        <zip>CH63 45Y</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE4 6BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Northwood</city>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Peterborough</city>
        <zip>PE 3 9GZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sheffield</city>
        <zip>S1O 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stoke-on-trent</city>
        <zip>ST4 7LN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Truro</city>
        <zip>TR1 3LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wolverhampton</city>
        <zip>WV10 0QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bosnia and Herzegovina</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>China</country>
    <country>Costa Rica</country>
    <country>Czech Republic</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hong Kong</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Macedonia, The Former Yugoslav Republic of</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Singapore</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Former Serbia and Montenegro</country>
  </removed_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2007</study_first_submitted>
  <study_first_submitted_qc>September 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2007</study_first_posted>
  <results_first_submitted>February 28, 2013</results_first_submitted>
  <results_first_submitted_qc>June 28, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 10, 2013</results_first_posted>
  <last_update_submitted>August 5, 2015</last_update_submitted>
  <last_update_submitted_qc>August 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bevacizumab and Chemotherapy</title>
          <description>Participants randomized to receive bevacizumab and chemotherapy.
For these patients, bevacizumab was given in combination with chemotherapy at a dose of 5 mg/kg/week equivalent using 1 of 3 different scheduling options depending on the schedule of the adjuvant chemotherapy selected. After completing chemotherapy + bevacizumab (treatment period 1), patients in this arm received bevacizumab monotherapy up to a total duration of 1 year (treatment period 2).
At the end of treatment (i.e., after approximately 55 weeks), patients were followed up until the end of the study.</description>
        </group>
        <group group_id="P2">
          <title>Chemotherapy</title>
          <description>Participants randomized to receive chemotherapy alone.
For patients randomized to the chemotherapy alone arm, investigators could select from one of three chemotherapy regimens. After completing chemotherapy (treatment period 1) patients entered a post-treatment surveillance period for the remainder of the first year after randomization (treatment period 2).
At the end of treatment (i.e., after approximately 55 weeks), patients were followed up until the end of the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1301"/>
                <participants group_id="P2" count="1290"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intention to Treat</title>
              <participants_list>
                <participants group_id="P1" count="1301"/>
                <participants group_id="P2" count="1290"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="1288"/>
                <participants group_id="P2" count="1271"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="870"/>
                <participants group_id="P2" count="982"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="431"/>
                <participants group_id="P2" count="308"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Breast Cancer Recurrence/2nd Primary</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event/Intermittent Illness</title>
              <participants_list>
                <participants group_id="P1" count="255"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Violation Criteria at Entry</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused Treatment/Did Not Cooperate</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failure to Return</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative/Other</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bevacizumab and Chemotherapy</title>
          <description>Participants randomized to receive bevacizumab and chemotherapy</description>
        </group>
        <group group_id="B2">
          <title>Chemotherapy</title>
          <description>Participants randomized to receive chemotherapy alone</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1301"/>
            <count group_id="B2" value="1290"/>
            <count group_id="B3" value="2591"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="231"/>
                    <measurement group_id="B2" value="253"/>
                    <measurement group_id="B3" value="484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 40 to &lt; 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="952"/>
                    <measurement group_id="B2" value="916"/>
                    <measurement group_id="B3" value="1868"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="121"/>
                    <measurement group_id="B3" value="239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1301"/>
                    <measurement group_id="B2" value="1290"/>
                    <measurement group_id="B3" value="2591"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Invasive Disease-free Survival (IDFS) Event</title>
        <description>IDFS, was a composite endpoint defined as the time from randomization until the date of the first occurrence of one of the following events: Ipsilateral invasive breast cancer recurrence (same breast); Ipsilateral (same side of body) local regional invasive breast cancer recurrence (axilla, regional lymph nodes, chest wall, and/or skin); Distant recurrence (evidence of breast cancer in any anatomic site);Death attributable to any cause; Contralateral (opposite side of the body) invasive breast cancer or Second primary non-breast invasive cancer.</description>
        <time_frame>Event driven (until data cutoff: 29 February 2012: up to 49 months)</time_frame>
        <population>Intent-to-treat population, defined as all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab and Chemotherapy</title>
            <description>Participants randomized to receive bevacizumab and chemotherapy</description>
          </group>
          <group group_id="O2">
            <title>Chemotherapy</title>
            <description>Participants randomized to receive chemotherapy alone</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Invasive Disease-free Survival (IDFS) Event</title>
          <description>IDFS, was a composite endpoint defined as the time from randomization until the date of the first occurrence of one of the following events: Ipsilateral invasive breast cancer recurrence (same breast); Ipsilateral (same side of body) local regional invasive breast cancer recurrence (axilla, regional lymph nodes, chest wall, and/or skin); Distant recurrence (evidence of breast cancer in any anatomic site);Death attributable to any cause; Contralateral (opposite side of the body) invasive breast cancer or Second primary non-breast invasive cancer.</description>
          <population>Intent-to-treat population, defined as all randomized participants.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1301"/>
                <count group_id="O2" value="1290"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The median was not reached.</measurement>
                    <measurement group_id="O2" value="NA">The median was not reached.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1810</p_value>
            <method>Log Rank</method>
            <method_desc>Stratification factors were axillary nodal status, choice of adjuvant chemotherapy, hormone receptor status, surgery.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Overall Survival (OS) Event</title>
        <description>OS was defined as the time from randomization to death attributable to any cause. Patients for whom no death is captured in the clinical database up to the clinical cut-off date are censored at the last time they were known to be alive.</description>
        <time_frame>Event driven (until data cutoff: 29 February 2012: up to 49 months)</time_frame>
        <population>Intent-to-treat population, defined as all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab and Chemotherapy</title>
            <description>Participants randomized to receive bevacizumab and chemotherapy</description>
          </group>
          <group group_id="O2">
            <title>Chemotherapy</title>
            <description>Participants randomized to receive chemotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Overall Survival (OS) Event</title>
          <description>OS was defined as the time from randomization to death attributable to any cause. Patients for whom no death is captured in the clinical database up to the clinical cut-off date are censored at the last time they were known to be alive.</description>
          <population>Intent-to-treat population, defined as all randomized participants.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1301"/>
                <count group_id="O2" value="1290"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The median was not reached</measurement>
                    <measurement group_id="O2" value="NA">The median was not reached</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Overall Survival (OS) Event</title>
        <description>OS was defined as the time from randomization to death attributable to any cause. Patients for whom no death is captured in the clinical database up to the clinical cut-off date are censored at the last time they were known to be alive.</description>
        <time_frame>Event driven (until data cutoff: 30 June 2014: up to 77 months)</time_frame>
        <population>Intent-to-treat population, defined as all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab and Chemotherapy</title>
            <description>Participants randomized to receive bevacizumab and chemotherapy</description>
          </group>
          <group group_id="O2">
            <title>Chemotherapy</title>
            <description>Participants randomized to receive chemotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Overall Survival (OS) Event</title>
          <description>OS was defined as the time from randomization to death attributable to any cause. Patients for whom no death is captured in the clinical database up to the clinical cut-off date are censored at the last time they were known to be alive.</description>
          <population>Intent-to-treat population, defined as all randomized participants.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1301"/>
                <count group_id="O2" value="1290"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The median was not estimable.</measurement>
                    <measurement group_id="O2" value="NA">The median was not estimable.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5247</p_value>
            <method>Log Rank</method>
            <method_desc>Stratification factors are Axillary nodal status, Choice of adjuvant chemotherapy, Hormone receptor status, Surgery</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Invasive Disease-free Survival (IDFS) Events</title>
        <description>IDFS, was a composite endpoint defined as the time from randomization until the date of the first occurrence of one of the following events: Ipsilateral invasive breast cancer recurrence (same breast); Ipsilateral (same side of body) local regional invasive breast cancer recurrence (axilla, regional lymph nodes, chest wall, and/or skin); Distant recurrence (evidence of breast cancer in any anatomic site);Death attributable to any cause; Contralateral (opposite side of the body) invasive breast cancer or Second primary non-breast invasive cancer. The percentage of participants with and without IDFS Events by the time of the data cutoff is presented.</description>
        <time_frame>Event driven (until data cutoff: 29 February 2012 up to 49 months)</time_frame>
        <population>Intent-to-treat population, defined as all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab and Chemotherapy</title>
            <description>Participants randomized to receive bevacizumab and chemotherapy</description>
          </group>
          <group group_id="O2">
            <title>Chemotherapy</title>
            <description>Participants randomized to receive chemotherapy alone</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Invasive Disease-free Survival (IDFS) Events</title>
          <description>IDFS, was a composite endpoint defined as the time from randomization until the date of the first occurrence of one of the following events: Ipsilateral invasive breast cancer recurrence (same breast); Ipsilateral (same side of body) local regional invasive breast cancer recurrence (axilla, regional lymph nodes, chest wall, and/or skin); Distant recurrence (evidence of breast cancer in any anatomic site);Death attributable to any cause; Contralateral (opposite side of the body) invasive breast cancer or Second primary non-breast invasive cancer. The percentage of participants with and without IDFS Events by the time of the data cutoff is presented.</description>
          <population>Intent-to-treat population, defined as all randomized participants.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1301"/>
                <count group_id="O2" value="1290"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage of Participants with Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5"/>
                    <measurement group_id="O2" value="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of Participants without Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.5"/>
                    <measurement group_id="O2" value="84.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Invasive Disease-free Survival (IDFS) Event Excluding Second Primary Non-Breast Invasive Cancer</title>
        <description>IDFS, was a composite endpoint defined as the time from randomization until the date of the first occurrence of one of the following events: Ipsilateral invasive breast cancer recurrence (same breast); Ipsilateral (same side of body) local regional invasive breast cancer recurrence (axilla, regional lymph nodes, chest wall, and/or skin); Distant recurrence (evidence of breast cancer in any anatomic site); Death attributable to any cause; Contralateral (opposite side of the body) invasive breast cancer.</description>
        <time_frame>Event driven (until data cutoff: 29 February 2012: up to 49 months)</time_frame>
        <population>Intent-to-treat population, defined as all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab and Chemotherapy</title>
            <description>Participants randomized to receive bevacizumab and chemotherapy</description>
          </group>
          <group group_id="O2">
            <title>Chemotherapy</title>
            <description>Participants randomized to receive chemotherapy alone</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Invasive Disease-free Survival (IDFS) Event Excluding Second Primary Non-Breast Invasive Cancer</title>
          <description>IDFS, was a composite endpoint defined as the time from randomization until the date of the first occurrence of one of the following events: Ipsilateral invasive breast cancer recurrence (same breast); Ipsilateral (same side of body) local regional invasive breast cancer recurrence (axilla, regional lymph nodes, chest wall, and/or skin); Distant recurrence (evidence of breast cancer in any anatomic site); Death attributable to any cause; Contralateral (opposite side of the body) invasive breast cancer.</description>
          <population>Intent-to-treat population, defined as all randomized participants.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1301"/>
                <count group_id="O2" value="1290"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The median was not reached.</measurement>
                    <measurement group_id="O2" value="NA">The median was not reached.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1966</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
            <estimate_desc>Stratification factors were axillary nodal status, choice of adjuvant chemotherapy, hormone receptor status, surgery.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Overall Survival (OS) Event</title>
        <description>OS was defined as the time from randomization to death attributable to any cause. Patients for whom no death is captured in the clinical database up to the clinical cut-off date are censored at the last time they were known to be alive.</description>
        <time_frame>Event driven (until data cut off: 29 February 2012: up to 49 months)</time_frame>
        <population>Intent-to-treat population, defined as all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab and Chemotherapy</title>
            <description>Participants randomized to receive bevacizumab and chemotherapy</description>
          </group>
          <group group_id="O2">
            <title>Chemotherapy</title>
            <description>Participants randomized to receive chemotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Overall Survival (OS) Event</title>
          <description>OS was defined as the time from randomization to death attributable to any cause. Patients for whom no death is captured in the clinical database up to the clinical cut-off date are censored at the last time they were known to be alive.</description>
          <population>Intent-to-treat population, defined as all randomized participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1301"/>
                <count group_id="O2" value="1290"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>with events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1"/>
                    <measurement group_id="O2" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>without events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.9"/>
                    <measurement group_id="O2" value="91.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2318</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Invasive Disease-free Survival (IDFS) Events Excluding Second Primary Non-Breast Invasive Cancer</title>
        <description>IDFS, was a composite endpoint defined as the time from randomization until the date of the first occurrence of one of the following events: Ipsilateral invasive breast cancer recurrence (same breast); Ipsilateral (same side of body) local regional invasive breast cancer recurrence (axilla, regional lymph nodes, chest wall, and/or skin); Distant recurrence (evidence of breast cancer in any anatomic site); Death attributable to any cause; Contralateral (opposite side of the body) invasive breast cancer. Percentage of participants with and without IDFS Events by the time of data cutoff is presented.</description>
        <time_frame>Event driven (until data cutoff: 29 February 2012: up to 49 months)</time_frame>
        <population>Intent-to-treat population, defined as all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab and Chemotherapy</title>
            <description>Participants randomized to receive bevacizumab and chemotherapy</description>
          </group>
          <group group_id="O2">
            <title>Chemotherapy</title>
            <description>Participants randomized to receive chemotherapy alone</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Invasive Disease-free Survival (IDFS) Events Excluding Second Primary Non-Breast Invasive Cancer</title>
          <description>IDFS, was a composite endpoint defined as the time from randomization until the date of the first occurrence of one of the following events: Ipsilateral invasive breast cancer recurrence (same breast); Ipsilateral (same side of body) local regional invasive breast cancer recurrence (axilla, regional lymph nodes, chest wall, and/or skin); Distant recurrence (evidence of breast cancer in any anatomic site); Death attributable to any cause; Contralateral (opposite side of the body) invasive breast cancer. Percentage of participants with and without IDFS Events by the time of data cutoff is presented.</description>
          <population>Intent-to-treat population, defined as all randomized participants.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1301"/>
                <count group_id="O2" value="1290"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage of Participants with Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5"/>
                    <measurement group_id="O2" value="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of Participants without Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.5"/>
                    <measurement group_id="O2" value="85.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Overall Survival (OS) Event</title>
        <description>OS was defined as the time from randomization to death attributable to any cause. Patients for whom no death is captured in the clinical database up to the clinical cut-off date are censored at the last time they were known to be alive.</description>
        <time_frame>Event driven (until data cut off: 30 June 2014: up to 77 months)</time_frame>
        <population>Intent-to-treat population, defined as all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab and Chemotherapy</title>
            <description>Participants randomized to receive bevacizumab and chemotherapy</description>
          </group>
          <group group_id="O2">
            <title>Chemotherapy</title>
            <description>Participants randomized to receive chemotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Overall Survival (OS) Event</title>
          <description>OS was defined as the time from randomization to death attributable to any cause. Patients for whom no death is captured in the clinical database up to the clinical cut-off date are censored at the last time they were known to be alive.</description>
          <population>Intent-to-treat population, defined as all randomized participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1301"/>
                <count group_id="O2" value="1290"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>with events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1"/>
                    <measurement group_id="O2" value="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>without events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.9"/>
                    <measurement group_id="O2" value="88.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Breast Cancer-Free Interval (BCFI) Event</title>
        <description>BCFI is defined as the time from randomization until the date of the first occurrence of one of the following events: Ipsilateral local/regional invasive breast cancer recurrence or distant breast cancer recurrence; Contralateral invasive breast cancer; Ipsilateral or contralateral Ductal carcinoma in situ or Death only from breast cancer cause.</description>
        <time_frame>Event driven (until data cutoff: 29 February 2012: up to 49 months)</time_frame>
        <population>Intent-to-treat participants, defined as all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab and Chemotherapy</title>
            <description>Participants randomized to receive bevacizumab and chemotherapy</description>
          </group>
          <group group_id="O2">
            <title>Chemotherapy</title>
            <description>Participants randomized to receive chemotherapy alone</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Breast Cancer-Free Interval (BCFI) Event</title>
          <description>BCFI is defined as the time from randomization until the date of the first occurrence of one of the following events: Ipsilateral local/regional invasive breast cancer recurrence or distant breast cancer recurrence; Contralateral invasive breast cancer; Ipsilateral or contralateral Ductal carcinoma in situ or Death only from breast cancer cause.</description>
          <population>Intent-to-treat participants, defined as all randomized participants.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1301"/>
                <count group_id="O2" value="1290"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The median was not reached.</measurement>
                    <measurement group_id="O2" value="NA">The median was not reached.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2792</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
            <estimate_desc>Stratification factors were axillary nodal status, choice of adjuvant chemotherapy, hormone receptor status, surgery.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Breast Cancer-Free Interval (BCFI) Events</title>
        <description>BCFI is defined as the time from randomization until the date of the first occurrence of one of the following events: Ipsilateral local/regional invasive breast cancer recurrence or distant breast cancer recurrence; Contralateral invasive breast cancer; Ipsilateral or contralateral DCIS or Death only from breast cancer cause. Percentage of participants with and without BCFI events by the time of the data cutoff is presented.</description>
        <time_frame>Event driven (until data cutoff: 29 February 2012: up to 49 months)</time_frame>
        <population>Intent-to-treat population, defined as all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab and Chemotherapy</title>
            <description>Participants randomized to receive bevacizumab and chemotherapy</description>
          </group>
          <group group_id="O2">
            <title>Chemotherapy</title>
            <description>Participants randomized to receive chemotherapy alone</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Breast Cancer-Free Interval (BCFI) Events</title>
          <description>BCFI is defined as the time from randomization until the date of the first occurrence of one of the following events: Ipsilateral local/regional invasive breast cancer recurrence or distant breast cancer recurrence; Contralateral invasive breast cancer; Ipsilateral or contralateral DCIS or Death only from breast cancer cause. Percentage of participants with and without BCFI events by the time of the data cutoff is presented.</description>
          <population>Intent-to-treat population, defined as all randomized participants.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1301"/>
                <count group_id="O2" value="1290"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage of Participants with Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2"/>
                    <measurement group_id="O2" value="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of Participants without Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.8"/>
                    <measurement group_id="O2" value="85.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Disease-Free Survival (DFS) Event</title>
        <description>DFS is defined as the time from randomization until the date of the first occurrence of one of the following events: Ipsilateral invasive breast cancer recurrence (same breast); Ipsilateral (same side of body) local regional invasive breast cancer recurrence (axilla, regional lymph nodes, chest wall, and/or skin); Distant recurrence (evidence of breast cancer in any anatomic site); Death attributable to any cause; Contralateral (opposite side of the body) invasive breast cancer, Second primary non-breast invasive cancer or New diagnosis of an ipsilateral or contralateral Ductal carcinoma in situ (DCIS).</description>
        <time_frame>Event driven (until data cutoff: 29 February 2012: up to 49 months)</time_frame>
        <population>Intent-to-treat population, defined as all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab and Chemotherapy</title>
            <description>Participants randomized to receive bevacizumab and chemotherapy</description>
          </group>
          <group group_id="O2">
            <title>Chemotherapy</title>
            <description>Participants randomized to receive chemotherapy alone</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Disease-Free Survival (DFS) Event</title>
          <description>DFS is defined as the time from randomization until the date of the first occurrence of one of the following events: Ipsilateral invasive breast cancer recurrence (same breast); Ipsilateral (same side of body) local regional invasive breast cancer recurrence (axilla, regional lymph nodes, chest wall, and/or skin); Distant recurrence (evidence of breast cancer in any anatomic site); Death attributable to any cause; Contralateral (opposite side of the body) invasive breast cancer, Second primary non-breast invasive cancer or New diagnosis of an ipsilateral or contralateral Ductal carcinoma in situ (DCIS).</description>
          <population>Intent-to-treat population, defined as all randomized participants.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1301"/>
                <count group_id="O2" value="1290"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The median was not reached.</measurement>
                    <measurement group_id="O2" value="NA">The median was not reached.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1832</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
            <estimate_desc>Stratification factors were axillary nodal status, choice of adjuvant chemotherapy, hormone receptor status, surgery.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Disease-Free Survival (DFS) Events</title>
        <description>DFS is defined as the time from randomization until the date of the first occurrence of one of the following events: Ipsilateral invasive breast cancer recurrence (same breast); Ipsilateral (same side of body) local regional invasive breast cancer recurrence (axilla, regional lymph nodes, chest wall, and/or skin); Distant recurrence (evidence of breast cancer in any anatomic site); Death attributable to any cause; Contralateral (opposite side of the body) invasive breast cancer, Second primary non-breast invasive cancer or New diagnosis of an ipsilateral or contralateral Ductal carcinoma in situ (DCIS). Percentage of Participants with and without DFI Events by the time of the data cut-off is presented.</description>
        <time_frame>Event driven (until data cutoff: 29 February 2012: up to 49 months)</time_frame>
        <population>Intent-to-treat population, defined as all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab and Chemotherapy</title>
            <description>Participants randomized to receive bevacizumab and chemotherapy</description>
          </group>
          <group group_id="O2">
            <title>Chemotherapy</title>
            <description>Participants randomized to receive chemotherapy alone</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Disease-Free Survival (DFS) Events</title>
          <description>DFS is defined as the time from randomization until the date of the first occurrence of one of the following events: Ipsilateral invasive breast cancer recurrence (same breast); Ipsilateral (same side of body) local regional invasive breast cancer recurrence (axilla, regional lymph nodes, chest wall, and/or skin); Distant recurrence (evidence of breast cancer in any anatomic site); Death attributable to any cause; Contralateral (opposite side of the body) invasive breast cancer, Second primary non-breast invasive cancer or New diagnosis of an ipsilateral or contralateral Ductal carcinoma in situ (DCIS). Percentage of Participants with and without DFI Events by the time of the data cut-off is presented.</description>
          <population>Intent-to-treat population, defined as all randomized participants.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1301"/>
                <count group_id="O2" value="1290"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>with Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7"/>
                    <measurement group_id="O2" value="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>without Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.3"/>
                    <measurement group_id="O2" value="83.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Distant Disease-Free Survival (DDFS) Event</title>
        <description>DDFS is defined as the time from randomization until the date of the first occurrence of one of the following events: Distant recurrence; Death attributable to any cause; Second primary non-breast invasive cancer (with the exception of non-melanoma Skin cancers).</description>
        <time_frame>Event driven (until data cutoff: 29 February 2012: up to 49 months)</time_frame>
        <population>Intent-to-treat population, defined as all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab and Chemotherapy</title>
            <description>Participants randomized to receive bevacizumab and chemotherapy</description>
          </group>
          <group group_id="O2">
            <title>Chemotherapy</title>
            <description>Participants randomized to receive chemotherapy alone</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Distant Disease-Free Survival (DDFS) Event</title>
          <description>DDFS is defined as the time from randomization until the date of the first occurrence of one of the following events: Distant recurrence; Death attributable to any cause; Second primary non-breast invasive cancer (with the exception of non-melanoma Skin cancers).</description>
          <population>Intent-to-treat population, defined as all randomized participants.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1301"/>
                <count group_id="O2" value="1290"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The median was not reached.</measurement>
                    <measurement group_id="O2" value="NA">The median was not reached</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3309</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
            <estimate_desc>Stratification factors were axillary nodal status, choice of adjuvant chemotherapy, hormone receptor status, surgery.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Distant Disease-Free Survival (DDFS) Events</title>
        <description>DDFS is defined as the time from randomization until the date of the first occurrence of one of the following events: Distant recurrence; Death attributable to any cause; Second primary non-breast invasive cancer (with the exception of non-melanoma Skin cancers). Percentage of participants with and without DDFS Events by the time of the data cutoff is presented.</description>
        <time_frame>Event driven (until data cutoff: 29 February 2012: up to 49 months)</time_frame>
        <population>Intent-to-treat population, defined as all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab and Chemotherapy</title>
            <description>Participants randomized to receive bevacizumab and chemotherapy</description>
          </group>
          <group group_id="O2">
            <title>Chemotherapy</title>
            <description>Participants randomized to receive chemotherapy alone</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Distant Disease-Free Survival (DDFS) Events</title>
          <description>DDFS is defined as the time from randomization until the date of the first occurrence of one of the following events: Distant recurrence; Death attributable to any cause; Second primary non-breast invasive cancer (with the exception of non-melanoma Skin cancers). Percentage of participants with and without DDFS Events by the time of the data cutoff is presented.</description>
          <population>Intent-to-treat population, defined as all randomized participants.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1301"/>
                <count group_id="O2" value="1290"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage of Participants with Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7"/>
                    <measurement group_id="O2" value="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of Participants without Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.3"/>
                    <measurement group_id="O2" value="87.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Adverse Events (SAEs), Adverse Events (AEs) and Deaths</title>
        <description>An adverse event was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events.
A serious adverse event is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is Life-Threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.</description>
        <time_frame>Through end of study: 30 June 2014: up to 77 months</time_frame>
        <population>Safety population, defined as all randomized participants who received at least one dose of study drug. Participants who received at least one full or partial dose of bevacizumab were included in the bevacizumab and chemotherapy arm; all other patients were analyzed in the chemotherapy arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab and Chemotherapy (0-18 Months)</title>
            <description>Occurring in participants who received bevacizumab and chemotherapy, 0-18 months after first dose</description>
          </group>
          <group group_id="O2">
            <title>Chemotherapy (0-18 Months)</title>
            <description>Occurring in participants who received chemotherapy alone, 0-18 months after first dose</description>
          </group>
          <group group_id="O3">
            <title>Bevacizumab and Chemotherapy (&gt;18 Months)</title>
            <description>Occurring in participants who received bevacizumab and chemotherapy, more than 18 months after first dose</description>
          </group>
          <group group_id="O4">
            <title>Chemotherapy (&gt;18 Months)</title>
            <description>Occurring in participants who received chemotherapy alone, more than 18 months after first dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events (SAEs), Adverse Events (AEs) and Deaths</title>
          <description>An adverse event was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events.
A serious adverse event is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is Life-Threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.</description>
          <population>Safety population, defined as all randomized participants who received at least one dose of study drug. Participants who received at least one full or partial dose of bevacizumab were included in the bevacizumab and chemotherapy arm; all other patients were analyzed in the chemotherapy arm.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1288"/>
                <count group_id="O2" value="1271"/>
                <count group_id="O3" value="1288"/>
                <count group_id="O4" value="1271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="379"/>
                    <measurement group_id="O2" value="250"/>
                    <measurement group_id="O3" value="45"/>
                    <measurement group_id="O4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse Events (5% Reporting Threshold)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1268"/>
                    <measurement group_id="O2" value="1233"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="113"/>
                    <measurement group_id="O4" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through end of study, 30 June 2014</time_frame>
      <desc>The analysis set was the safety population, defined as all randomized participants who received at least one dose of study drug. Participants who received at least one full or partial dose of bevacizumab were included in the bevacizumab and chemotherapy arm; all others, in the chemotherapy arm. MedDRA (15.0) and MedDRA (17.0) were used.</desc>
      <group_list>
        <group group_id="E1">
          <title>Bevacizumab and Chemotherapy (0-18 Months)</title>
          <description>Occurring in participants who received bevacizumab and chemotherapy, during treatment period (0-18 months) after first dose</description>
        </group>
        <group group_id="E2">
          <title>Chemotherapy (0-18 Months)</title>
          <description>Occurring in participants who received chemotherapy alone, during treatment period (0-18 months) after first dose</description>
        </group>
        <group group_id="E3">
          <title>Bevacizumab and Chemotherapy (&gt;18 Months)</title>
          <description>Occurring in participants who received bevacizumab and chemotherapy, during follow-up period (&gt;18 months) after first dose</description>
        </group>
        <group group_id="E4">
          <title>Chemotherapy (&gt;18 Months)</title>
          <description>Occurring in participants who received chemotherapy alone, during follow-up period (&gt;18 months) after first dose</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="379" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="250" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="48" subjects_at_risk="1271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Febrile bone marrow aplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Atrial thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Mitral valve disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Basedow's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism primary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Gaze palsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Caecitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Diverticulitis intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Enterocolonic fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Gingival ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Neutropenic colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Rectal polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Crohns Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Thrombosis in device</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Device damage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Patient-device incompatibility</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Catheter site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Catheter site inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Device deployment issue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Device extrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Extravasation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Lipogranuloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Hepatic lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Neutropenic infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Mastitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Breast cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Abscess oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Bartholin's abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Breast infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Catheter site cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Catheter site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Herpes zoster disseminated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Lymph node abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Peritonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Pilonidal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Pneumocystis jiroveci pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Pseudomonal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Salpingo-oophoritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Wound abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Wound complication</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Coronary artery restenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>In-stent coronary artery restenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Radiation skin injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Periprosthetic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Radiation pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Blood pressure decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Cytology abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Influenza A virus test positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Benign breast neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Antiomyolipoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Bowens disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Haemangioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Oesophageal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Ovarian fibroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Uterine Leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Posterior reversible encephalopathy syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Hypoxic-ischaemic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Hyperemesis gravidarum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Premature delivery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Conversion disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>IGA nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Stress urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Bartholin's cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Breast cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Breast haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Vaginal ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Adenomyosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Breast calcifications</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Breast mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Dysfunctional uterine bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Vaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Nasal septum perforation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Pharyngeal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Pulmonary artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Vocal cord polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Skin necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Hypertrophic scar</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Breast prosthesis implantation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Rehabilitation therapy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Arterial thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1268" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="1233" subjects_at_risk="1271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1288"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="503" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="479" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="210" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="215" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="140" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="175" subjects_at_risk="1271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="261" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="165" subjects_at_risk="1271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="156" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="109" subjects_at_risk="1271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="881" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="880" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="663" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="469" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="480" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="459" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="444" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="401" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="418" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="350" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="201" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="165" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="138" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="112" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="123" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="124" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" subjects_affected="138" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="1271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="533" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="539" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="230" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="223" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="214" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="164" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="145" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="164" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="1271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="137" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="125" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="109" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="1271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Radiation skin injury</sub_title>
                <counts group_id="E1" subjects_affected="151" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="190" subjects_at_risk="1271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="1271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="260" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="223" subjects_at_risk="1271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="414" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="252" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="278" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="273" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="198" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="171" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="172" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="141" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="111" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="162" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="123" subjects_at_risk="1271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="440" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="289" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="243" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="230" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="138" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="135" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="137" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="128" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="130" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="121" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="1271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="191" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="217" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="1271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="195" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="1271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="1271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="478" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="215" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="161" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="179" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="99" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="144" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="123" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="104" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="1271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="807" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="833" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" subjects_affected="183" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="150" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="160" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="137" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="114" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Palmar-Plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="1271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="456" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="206" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="208" subjects_at_risk="1271"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="1288"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="1271"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffman-LaRoche</organization>
      <phone>800-821-8590</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

